Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Systemic sclerosis
•
Scleroderma
•
Eosinophilic Fasciitis
How do you approach initial steroid dosing in patients with eosinophilic fasciitis?
When do you consider adding steroid sparing agents?
Related Questions
How do you approach the significance of +RNP III antibody in a patient with positive ANA but no other signs or symptoms of systemic sclerosis?
In patients with diffuse scleroderma and symptomatic lower extremity venous insufficiency, would you recommend treatment with endovenous laser/ablation?
Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
What are some important considerations for use of ACE inhibition in scleroderma renal crisis patients who require dialysis?
What is the clinical significance of an isolated anti-centromere B antibody in a patient with pulmonary fibrosis but no other features of systemic sclerosis?
How do you envision incorporating CAR-T therapy into your clinical practice?
What treatment regimen would you recommend for a patient with biopsy-proven giant cell arteritis and diffuse cutaneous systemic sclerosis?
How do you approach management of a patient presenting with clinical manifestations of systemic sclerosis (cutaneous involvement, Raynaud’s phenomenon, and pulmonary arterial hypertension) but negative serologies?
If a patient has progression of scleroderma-ILD on MMF alone, and you are planning to start tocilizumab, would you continue MMF at a lower dose to maintain skin softening?